Arovella Therapeutics Limited (AU:ALA) has released an update.
Arovella Therapeutics Limited (ASX: ALA), a biotech firm specializing in innovative cell therapies for cancer treatment, has announced the issuance of 719,424 ordinary shares. The share release, completed without disclosure under certain parts of the Corporations Act, complies with all necessary provisions and does not contain any undisclosed ‘excluded information’. Arovella continues to develop its leading CAR19-iNKT cell product, ALA-101, to target blood cancers and is expanding its technology for solid tumor treatments.
For further insights into AU:ALA stock, check out TipRanks’ Stock Analysis page.
